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Editorial on the Research Topic
Pulmonary Hypertension: Mechanisms and Management, History and Future
From pulmonary hypertension observed at high altitude to pulmonary hypertension associated
with left heart disease, this Frontiers Research Topic illustrates the diversity of clinical and
pathological phenotypes associated with elevated pressure in the pulmonary circulation. The topic
articles highlight the breadth of ongoing research into understanding this multi-faceted disease
and are based on the content of a symposium that drew inspiration from the work of the British
pathologist, Donald Heath, who published his manuscript on hypertensive pulmonary vascular
disease after working as junior doctor in Sheffield (1, 2).
Despite advances in therapy over the last two decades, most forms of pulmonary hypertension
(PH) have a poor prognosis. The greatest improvements in outcome have been observed in patients
with CTEPH (3) where surgery may provide a cure, and pulmonary arterial hypertension (PAH)
where younger patients with idiopathic disease (IPAH) in the UK now have a 5-year survival in
excess of 80% (4). Intuitively, earlier diagnosis and institution of treatment may slow vascular
remodeling and improve outcomes. However, despite increased awareness and the availability
of new therapies the time from symptom onset to diagnosis remains unchanged at 2–3 years,
suggesting that new approaches need to be taken to improve disease detection (5). This highlights
the importance of identifying easily performed and scalable tests that can be deployed in the
investigative pathway. Three of the studies in this Research Topic highlighted different modalities
used in the diagnosis of pulmonary hypertension: exercise, serological biomarkers, and imaging.
Billings et al. reported the utility of exercise testing in newly diagnosed, treatment naïve patients
with pulmonary hypertension. Although this was a large retrospective study, only a small number
of patients (1% of 895) were diagnosed while in WHO FC I. These data are consistent with early
vascular changes preceding the development of symptoms and highlight the need for effective
and sensitive screening tools for early disease. Billings et al. provide evidence that an incremental
shuttle walk distance (ISWD) of <80% predicted identified 8 out of 9 patients with pulmonary
hypertension in WHO FC I, while diffusing capacity (DLCO) measurements, using a cut-off of
80% predicted, only identified 4 of these patients. Further work is required to assess whether
the simple and adaptable incremental shuttle walk test is a suitable field walking test to identify
exercise limitation and to aid screening of high-risk populations, perhaps in combination with
other biomarkers.
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One such high risk group are those with connective
tissue diseases, particularly systemic sclerosis (6). Hickey et al.
discuss putative blood-based or lung tissue biomarkers for the
identification of systemic sclerosis patients who have developed
pulmonary hypertension. A significant issue with potential
biomarkers is heterogeneity of patient phenotype even within
this sub-group of PAH patients (7). Notably, the contribution of
co-morbid interstitial lung disease is difficult to unravel. Hickey
et al. also point out limitations associated with NT-proBNP,
perhaps the foremost blood-based biomarker for PH in clinical
use. While NT-proBNP features as an important component of
early screening algorithms for SSc-PAH (8), it lacks specificity
and carries the inherent disadvantage that the right ventricular
strain, driving its release, is not a feature of early disease.
The third study with a focus on enhancing diagnosis, Chin
et al., reports a strong correlation between CT measurement of
pulmonary artery diameter and mean pulmonary artery pressure
in the presence or absence of interstitial lung disease. This
report implies that use of simple CT parameters could help
predict presence of pulmonary hypertension in patients with
lung disease, contrasting with previous reports suggesting that
PA diameter was a less useful indicator of PH in patients
with interstitial lung disease. Nonetheless, however useful our
predictive tools, the armory of treatment of PH in these patients
with interstitial lung disease remains frustratingly empty.
Work on the role of hypoxia in vascular remodeling offers
potential promise for patients with PH associated with lung
disease. At a molecular level, the importance of hypoxia
inducible factors in vascular cell phenotypes is becoming clearer.
These oxygen sensors, the discovery of which was recently
acknowledged by the 2019 Nobel prize award to three HIF-
biologists, are discussed in a review by Young et al. and the
specific impact of altitude hypoxia on the pulmonary circulation
is highlighted.While hypoxia has a defining role in PH associated
with hypoxia and lung disease, the relevance of hypoxia at early
stages of the pathogenesis of other forms of PH is less clear.
One important mediator of vascular remodeling with a
potentially ubiquitous role across all forms of PH is neutrophil
elastase. Neutrophils are considered the dominant source of
elastase in vivo but as noted by Taylor et al., they are a relatively
understudied cell in PH. Nonetheless, an excess of neutrophils
(or high neutrophil to lymphocyte ratio) is reportedly correlated
with poor outcomes in patients with PH (9) and inhibition of
neutrophil elastase reversed disease in mouse models (10). The
effect of elastase on turnover of the vascular extracellular matrix,
and specifically changes resulting in stiffening of the large and
small pulmonary vessels, is the subject of the review by Sun
and Chan. Recent work from this group has shown that changes
in arterial stiffness precede proliferative remodeling and that
mechanosensitive pathways play important roles in regulating
vascular cell expansion (11).
The complexity of pro-proliferative signaling in the
pulmonary vasculature is further illustrated by the role of
TRAIL, reviewed by Braithwaite et al.. Cleavage of TRAIL,
a transmembrane protein, results in a soluble cytokine that
can signal via a number of cell surface receptors but can
also bind to decoy receptors. TRAIL canonically induces
apoptosis in cancer cells and in virus-infected epithelial cells
but paradoxically promotes vascular smooth muscle cell
proliferation. These contrasting effects are mediated by at
least two distinct signaling pathways and but exactly how cell
and context-specific effects of TRAIL are mediated requires
further study. Notably, the importance of TRAIL in infection,
fibrosis and cancer might complicate therapeutic targeting of
this pathway. However, other mediators known to interact
with TRAIL, such as osteoprotegerin, have shown therapeutic
promise (12).
Mechanistic insights are increasingly being generated by
omics studies (13, 14) and this burgeoning field is reviewed
by Hemnes. Blood-based or genetic signatures to enhance
the granularity of patient classification or simply to facilitate
diagnosis would have great utility, although relatively small
patient numbers limit power and validation of predictive
signatures. Furthermore, identifying whether omics are
capable of detecting changes that precede pulmonary vascular
remodeling will be challenging. Nonetheless, omics approaches
could not only be used to stratify or diagnose PH but could also
provide more personalized treatment approaches. Following
interesting work on patients with positive vasodilator responses
(15), Hemnes suggests using omics data to identify signatures
defining a good response with other treatments. The concept
of enriching clinical studies using specific omics signatures
and then refining those signatures based on clinical response is
proposed. Such strategies might increase the efficiency of later
phase clinical trials.
While the majority of topic articles focus on the pulmonary
circulation, Charalampopoulos et al. provide a comprehensive
overview of PH due to left heart disease. Echocardiographic
features that favor left heart disease over PAH are highlighted and
the authors discuss studies reporting use of fluid challenges or
exercise during right heart catheterization to identify occult left
heart disease. The question of whether pulmonary vasodilators
have any role in these patients or in patients with combined
pre- and post-capillary pulmonary hypertension is the subject
of ongoing clinical trials (e.g., SERENADE, NCT02246634) but
unfortunately for this large group of patients, there is as yet, no
clear answer.
The final review in the topic, by Middleton et al., notes the
lack of specific guidelines for arrhythmia management in PAH.
Indeed, there is a paucity of data on arrhythmia prevalence
and on how frequently arrhythmia contributes to death in
PAH patients. Deterioration in the context of atrial arrhythmia
is a common clinical scenario that is potentially reversible.
Therefore, exciting advances in monitoring technology,
including wearable or implantable monitors, are an important
avenue for future research. Indeed, our group are examining the
utility of invasive pulmonary artery pressure and implantable
rhythm monitors.
The broad and systematic approaches covered by the
manuscripts included in this Research Topic highlight many of
the current challenges to improve patient outcome and well-
being in PH. Earlier diagnosis of patients with PH remains a
major challenge. Despite advances in treatment and increasing
awareness of the disease over the last 2–3 decades, many patients
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arrive at specialist centers after a significant diagnostic delay (16).
While not reviewed in this topic, recent work from our center
has sought to improve this issue by highlighting the potential
use of artificial intelligence to interrogate routine healthcare data
in order to identify patients at high risk of idiopathic PAH
at an earlier stage (5). Furthermore, the topic only alludes to
the use of novel tools to phenotype these high-risk patients.
Multi-omic profiling and imaging of cardiac and lung structure
and function (17, 18) including the use of emerging techniques
such as hyperpolarised gases (19) or 4-dimensional magnetic
resonance imaging (20) will likely hold the key to developing
more sensitive and specific assessment tools. Such tools should
generate new insights into molecular targets that alter vascular
remodeling and could provide better clinical trial endpoints for
assessment of treatment efficacy. The development of biomarkers
and imaging tools using patients with earlier disease should be
a priority for improving the treatment of PH in the precision
medicine era.
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